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A B S T R A C T
Purpose: To longitudinally study surgical and hardware complications to vagal nerve stimulation (VNS)
treatment in patients with drug-resistant epilepsy.
Methods: In a longitudinal retrospective study, we analyzed surgical and hardware complications in 143
patients (81 men and 62 women) who between 1994 and 2010 underwent implantation of a VNS-device
for drug-resistant epilepsy. The mean follow-up time was 62  46 months and the total number of patient
years 738.
Results: 251 procedures were performed on 143 patients. 16.8% of the patients were afﬂicted by
complications related to surgery and 16.8% suffered from hardware malfunctions. Surgical complications
were: superﬁcial infection in 3.5%, deep infection needing explantation in 3.5%, vocal cord palsy in 5.6%,
which persisted in at least 0.7% for over one year, and other complications in 5.6%. Hardware-related
complications were: lead fracture in 11.9% of patients, disconnection in 2.8%, spontaneous turn-off in
1.4% and stimulator malfunction in 1.4%. We noted a tendency to different survival times between the
two most commonly used lead models as well as a tendency to increased infection rate with increasing
number of stimulator replacements.
Conclusion: In this series we report on surgical and hardware complications from our 16 years of
experience with VNS treatment. Infection following insertion of the VNS device and vocal cord palsy due
to damage to the vagus nerve are the most serious complications related to the surgery. Avoiding
unnecessary reoperations in order to reduce the appearances of these complications are of great
importance. It is therefore essential to minimize technical malfunctions that will lead to additional
surgery. Further studies are needed to evaluate the possible superiority of the modiﬁed leads.
Crown Copyright  2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
The prevalence of epilepsy is 0.5–1%.1 After adequate antiepi-
leptic drug-therapy, approximately one third still suffer from
seizures.2 Resective surgery, where the cortical location of the
onset of the seizures is resected, is one approach to decrease
seizure frequency in patients with partial epilepsy. In order for this
to be applied, the focus of the onset of the seizures needs to be
identiﬁed, dispensable and accessible for surgery. In cases when
this has proven not possible vagal nerve stimulation (VNS) has
emerged as a therapeutic option. The ﬁrst VNS implantation for the
treatment of drug-resistant epilepsy not suitable for resective
surgery was conducted in 1988.3 Over the years, patients with
primary generalized epilepsy which has been proven to be drug-* Corresponding author at: Department of Pharmacology and Clinical Neurosci-
ence, Umea˚ University, Section of Neurosurgery, Umea˚ University Hospital, SE
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http://dx.doi.org/10.1016/j.seizure.2013.06.011resistant have also become candidates for VNS treatment. The
positive effect of VNS in reducing seizure frequency has been
shown extensively.4,5 Complications due to surgery and hardware
malfunctions have not been evaluated as thoroughly. Vocal cord
palsy, transient bradycardia and infection are some of the
complications associated with the surgical procedure that have
been reported.6–8 Hardware malfunctions such as lead fracture,
disconnection between lead and stimulator, and stimulator
malfunction have previously been observed.6,9,10 VNS has been
an integrated tool in the management of drug-resistant epilepsy in
the epilepsy surgery program at Umea˚ University Hospital since
1994. The aim of this study is to describe surgical and hardware
complications related both to the implantation and to the
treatment course in patients with drug-resistant epilepsy receiving
VNS treatment at our department since 1994.
2. Methods
In a longitudinal retrospective study, we identiﬁed the patients
who between 1994 and 31 December, 2010, underwent
implantation of a VNS device (Cyberonics Inc., Houston, TX, USA). Published by Elsevier Ltd. All rights reserved.
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occurrence of surgical and hardware complications. The deﬁnition of
surgical complication used is that of Sokol and Wilson: ‘‘A surgical
complication is any undesirable, unintended, and direct result of an
operation affecting the patient, which would not have occurred had
the operation gone as well as could reasonably be hoped’’.11
Infection is a condition that led to an active treatment with
antibiotics. Hoarseness that persisted 15 days post surgery is
considered vocal cord palsy. Hardware complication is deﬁned as an
incident that meant that the device did not work properly.
2.1. Patients
All patients were worked up within the multidisciplinary
epilepsy surgery program at the Departments of Neurology,
Pediatrics, Neurophysiology, Neuroradiology and Neurosurgery
at the Umea˚ University Hospital, Sweden. They were all diagnosed
with drug-resistant epilepsy, either not suitable for resective
surgery or failure of the same.
2.2. Surgical procedure
Antibiotics are administered before skin incision. We used
cefuroxime (30 mg/kg or 3 g) until the end of 2010 when we
changed to cloxacillin (2 g). We use three different approaches, for
the placement of the stimulator, depending on the patient. The
most commonly used is a transverse incision approximately 3 cm
below the collarbone. An incision just behind the anterior axillary
line can be used to hide the scar. In one patient, we used a cranio-
caudal incision along the course of the bra strap. For the
implantation of the electrodes we used, in the very ﬁrst patients,
an incision along the sternocleidomastoid muscle. We soon
changed to a partial collar incision. With blunt and sharp dissection
the carotid sheath is entered. The nerve is identiﬁed and prepared
for approximately 4–5 cm. A vessel loop is run beneath the nerve
and used to hold the nerve while the electrode and anchor helices
are being applied around the nerve. The electrode is secured with
one anchor to the fascia of the medial muscles. The stimulator is
tested and connected to the electrode followed by another test to
verify that the system is functioning properly. The stimulator is
usually not anchored to the fascia of the pectoral muscle.
Stimulator replacements are done under local or general anesthe-
sia and with prophylactic antibiotics. Leads are replaced under
general anesthesia and with antibiotics.
2.3. Follow up
If no complications occurred the patient revisited the hospital
two weeks post surgery for initiation of the stimulation. This was
accomplished in three days by either the senior author or by a
single epilepsy nurse. The adjustment to our standard parameter
setting of 1.25 mA was reached in a great majority of the patients.
Patients were evaluated at our clinic for outcome and the
occurrence of complications every three months the ﬁrst year,
followed by yearly assessments. Medical charts from localTable 1
Patient characteristics.a
Mean age, SD, at
implantation, years
Median age (range) at
implantation, years
Men 25.4  15.4 22.9 (2.2–64.2) 
Women 30.7  15.6 31.7 (4.1–72.7) 
Adults 35.8  11.9 34 (18.1–72.7) 
Children 10.1  4.3 9.4 (2.2–17.8) 
Total 27.7  15.7 27.8 (2.2–72.7) 
a P, partial onset seizures; PG, primary generalized seizures.hospitals were collected from the time in which the patients
received treatment.
2.4. Statistics
Continuous variables are reported as means  standard devia-
tions. The median and range are also presented. Chi-squared is used
for the comparison of proportions. A Kaplan–Meier plot was used to
illustrate and analyze difference in lead survival time. A p-value of
<0.05 is considered to be statistically signiﬁcant. The statistical
software used is JMP 9.0.0 (SAS Institute Inc.)
2.5. Complication frequency
Complication frequency is reported as percentage in relation to
number of relevant procedures (npr) as well as the proportion of
patients that suffered from complication (npts). Calculation basis
npr or npts is shown after the percentage ﬁgure. The relevant
procedures chosen for the different complications are presented in
Table 3.
2.6. Ethics
The study was approved by the Regional Ethical Review Board
Umea, dnr 2011-214-31.
3. Results
We identiﬁed 143 patients who had had a VNS device
implanted between 1994 and 2010. Previous resective epilepsy
surgery had been done in 27 of these patients. Patient character-
istics are shown in Table 1.
The median follow-up time was 55 months (1–193) and the
mean follow-up time was 62  46 months. This corresponds to a total
treatment time of 738 years. 110 patients were still receiving
stimulation on 31 December 2010. Table 2 shows a summary of the
251 surgical procedures performed. The mean time to stimulator
replacement was 58  20.2 months and the median time 62 months
(0.25–98). For the stimulators that were replaced before end of power
the mean time to replacement was 66  9.8 months and for the
stimulators that were replaced because of end of power 62  13.5
months. We used a skin incision below the collarbone in the
midclavicular line in 79 patients and an incision in the anterior
axillary line in 63. The system was implanted on the left side in all cases
but two. Previous lymphoma on the left side of the neck was the reason
in one patient. The other presumably had extensive tissue adhesions
around the left vagus nerve as a result of infection during earlier left
VNS treatment. We noted 28 surgical (11.2% npr) and 25 hardware
(10.4% npr) complications in 40 patients (28% npts). 24 patients (16.8%
npts) were afﬂicted by complications related to surgery and 24 patients
(16.8% npts) suffered from hardware malfunctions. The total number of
individual patients who experienced any complication leading to a
surgical intervention was 25 (17.5% npts).
Table 3 summarizes all the complications.PG P Unclear classiﬁcation
of seizures
Total
25 56 0 81
15 46 1 62
30 67 1 98
10 35 0 45
40 102 1 143
Table 2
Summary of surgical procedures.
Surgical procedure n
VNS implantation 143
Plain stimulator replacement in one session 66
System replacement in one session (stimulator and lead) 6
Plain lead replacement in one session 9
Intentional lead replacement discontinued 1
Reconnection of lead to stimulator 4
Reposition of stimulator 2
Explantation of system (stimulator and lead) 9
Explantation of stimulator 5
Explantation of lead 2
Reimplantation of system (stimulator and lead) 3
Reimplantation of stimulator 1
Total surgical procedures 251
Table 3
Summary of the complications.A
Complications Numbers Incidence/
procedure
(%)
Proportion of the
patients (n 143)
with complication (%)
Surgical complications 28 11.2a 16.8
Infection (all) 12 5.0b 7.0
Explantation required 7 2.9 3.5
Vocal cord palsy (all) 8 4.6c 5.6
Post ﬁrst insertion 7 4.9d 4.9
Post lead explantation
or replacement
1 3.8e 4.2
Bradycardia 1 0.4f 0.7
Puncture of jugular vein 3 1.7g 2.1
During ﬁrst time insertion 1 0.7 0.7
During lead explantation
or replacement
2 7.7 8.3
Hematoma 1 0.4h 0.7
Large subcutaneous nerve
cut-off
1 0.4i 0.7
Keloid development 1 0.4j 0.7
Horner syndrome 1 0.6k 0.7
Technical complications 25 10.4l 16.8
Lead fracture 17 10.5m 11.9
Device malfunction 2 0.9n 1.4
Lead disconnection 4 1.8o 2.8
Spontaneous VNS turn off 2 0.9p 1.4
A a, relative frequency of incidents of complications among all surgical
procedures; b, relative frequency of incidents of infection among all procedures
excluding ex-plantations of parts of the device due to infection and ex-plantations
of the entire system; c, relative frequency of incidents of voice alteration that
remained for at least 15 days post surgery among all procedures on the neck
excluding procedures where voice alteration already existed; d, relative frequency
of incidents of voice alteration that remained for at least 15 days post ﬁrst time
insertion among all ﬁrst time insertions; e, relative frequency of incidents of voice
alteration that remained for at least 15 days post lead ex-plantation and
replacement among all lead ex-plantations and replacements; f, relative frequency
of incidents of bradycardia intra-operatively among all implantations, replace-
ments and reconnections; g, relative frequency of incidents of hemorrhage among
all procedures on the neck; h, relative frequency of incidents of hematoma among
all surgical procedures; i, relative frequency of incidents of nerve cut-off among all
surgical procedures; j, relative frequency of incidents of keloid development among
all surgical procedures; k, relative frequency of incidents of Horner syndrome
among all procedures on the neck; l, relative frequency of incidents of technical
complications among all surgical complications excluding explantations where all
parts were explanted; m, relative frequency of incidents of lead fracture among all
procedures where a new lead was inserted; n, relative frequency of device
malfunction among all stimulators inserted; o, relative frequency of incidents of
disconnection between stimulator and lead among all procedures excluding
explantations; p, relative frequency of incidents of systems spontaneously turning
off among all stimulators.
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Twelve incidents of infections were reported in ten patients
(7.0% npts), i.e. two patients were affected twice by an infection.
Each infection exclusively affected the region close to the
stimulator with two exceptions where the location of the lead,
close to the vagus nerve, was infected. Fig. 1 illustrates infection
frequencies in relation to the number of surgeries and patient age.
The differences in these infection frequencies are not statistically
signiﬁcant. Of the twelve infections seven (3.5% npts) had to be
treated with surgical removal of the device. After ﬁrst time
insertion three (2.1% npts) deep infections needing removal of the
generator occurred, and three (2.1% npts) superﬁcial infections,
only needing antibiotics, were identiﬁed. An infection needing
surgical intervention after stimulator replacement was found in 3
patients (3.9% of the replacements). After one case of stimulator
replacement (1.3% of the replacements) a superﬁcial infection was
observed and later successfully treated with antibiotics. In one
patient who experienced a deep infection around the stimulator
the stimulator was removed but the lead left in place and the
patient was treated with antibiotics. This patient was after the
treatment re-implanted with a new stimulator but soon after
developed a new infection which led to the explantation of the
entire system. The median time to the appearance of infection was
13 days (1–930) after the last surgery. Of the infections three
presented later than 3 months after surgery (182, 435, 930 days
after surgery), two of them needed surgical treatment. The mean
age of the patients with infection was 29.1  16.1 years. There was
no statistically signiﬁcant difference in infection frequency related to
the skin incision used.
Postoperative vocal cord palsy was seen in eight patients (5.6%
npts), as shown in Table 4.
One patient (0.7% npts) experienced an episode of bradycardia
during the intra-operative testing. Atropine was administered
intravenously and within one minute the cardiac rhythm had
normalized. Bradycardia did not occur during the initiation phase
two weeks later. The patient had no history of cardiac disorder
prior to the surgery. In three patients (2.1% npts), the jugular vein
was injured causing peroperative bleeding. One was a ﬁrst time
insertion and two occurred during lead revisions. In two cases, the
vein was repaired and the operation continued. In one case of lead
replacement, the procedure was interrupted and performed six
months later. In one case (0.7% npts), a superﬁcial cutaneous nerve
branch was cut. This patient suffered from hypoesthesia on the left
side of the neck after surgery. In one patient (0.7% npts), keloid
development was seen at the site of the incision on the neck. Signs
of Horner syndrome appeared in one patient (0.7% npts) in whom
left-sided miosis and ptosis were present subsequent to surgery.
The surgery was a ﬁrst time insertion and the symptoms arosebefore the initiation of stimulation. Computed tomography
angiography revealed no carotid dissection. The condition was
temporary but its duration could not be ascertained.
3.2. Technical complications
Totally 161 leads of 4 different types have been implanted. We
noted 17 lead breakages (11.9% npts and 10.5% of the leads). All
lead breakages affected the primary implanted lead. Of the ﬁrst
introduced lead model (300) 64 have been implanted. We changed
to lead model 302 in the midst of 2003 of which 92 have been
implanted. In 2010 two new models were introduced, 303 and 304,
of which we have implanted 3 and 2, respectively. Median time,
from implantation until explantation or end of study, was 93.5
months (3–192) for lead model 300 and for the model 302 the
corresponding time was 39 months (0–86). The number of lead
breakages noted in the 300 model was 13 (20.3% of the 300 leads)
and in model 302 4 (4.4% of the 302 leads) (p = 0.0016, Chi-square).
Looking at a survival analysis (Fig. 2), there was no statistically
signiﬁcant difference in the survival time between the two lead
Fig. 1. Bar graph demonstrating the infection frequencies (%) before and after one and two reoperations and stimulator replacements respectively, and the difference in
infection frequencies (%) between adults and children. (A) Relative frequency of infections occurring before replacement, reconnection, or repositioning among all patients
with a VNS implant. 6/143. (B) Relative frequency of infections occurring after one procedure (replacement, reconnection, or repositioning) among all patients that have
undergone at least one of these procedures. 4/63. (C) Relative frequency of infections occurring after two procedures (replacements, reconnections or repositionings) among
all patients that have undergone at least two of these procedures. 2/18. (D) Relative frequency of infections occurring before stimulator replacement among all patients with a
VNS implant. 7/143. (E) Relative frequency of infections occurring after one stimulator replacement among all patients who had undergone at least one stimulator
replacement. 3/57. (F) Relative frequency of infections occurring after two stimulator replacements among all patients who had undergone at least two stimulator
replacements. 2/14. (G) Relative frequency of infections occurring in patients who were over 18 years old when the last procedure was done among all procedures on patients
over 18 years old excluding explantations of parts of the device due to infection and explantations of the entire system. 8/170. (H) Relative frequency of infections occurring in
patients who were under 18 years old when the last procedure was done among all procedures on patients under 18 years old excluding explantations of parts of the device
due to infection and explantations of the entire system. 4/69.
Fig. 2. Kaplan–Meier plot over survival time of different models of leads.
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preceded by plain X-ray to identify lesions in 10 cases. Lesions
could be veriﬁed in 4 of these. No stimulator replacement had been
made prior to 14 of the 17 cases of lead breakage. In instance of
stimulator replacement, a breakage occurred while the electrode
pins were being removed from the stimulator. This lead had been
inserted 129 months before and corrosion between lead and
stimulator was observed. The mean time to lead breakage after
insertion was 42.9  41 months, median 37 months (0.6–129). The
median age of the patients when the breakage occurred was 25.8
years (6–59). There was no statistically signiﬁcant difference in leadTable 4
Summary of the vocal cord palsies.a
Vocal cord
palsy, no
Post system
implantation
or lead-explantation
Veriﬁed at the
Department of
Otolaryngology
Duration
(months)
1 SI Y 1.5
2 SI Y 12
3 SI Y 6
4 SI Y Subsided after 3
5 SI Y ?
6 SI N 1
7 SI N 1
8 LE N Prevalent after 12
a SI, implantation; LE, lead-explantation; N, no; Y, yes.breakage depending on the type of skin incision used. Two devices
(1.4% npts) appeared not to be working shortly after insertion.
Subsequent tests veriﬁed that these were non-functional devices. One
was a ﬁrst time insertion and the other occurred after replacement.
The stimulators were replaced after 8 and 29 months respectively
resulting in properly working devices. The reason for these
malfunctions is unclear. Disconnection between lead and stimulator
was seen in four cases in four patients (2.8% npts). No stimulator or
lead replacements had been made prior to these incidents. After
reconnection, all four systems worked properly. The times from VNS
insertion to disconnection were 24 days, 6, 7, and 11 months. The ages
of these patients at disconnection were 9, 39, 18, and 10 years
respectively. Two systems (1.4% npts) turned off spontaneously
during treatment. This occurred once in one patient, and twice in
another. They were both restarted and no explanation for these
malfunctions could be found.
4. Discussion
VNS treatment is considered to be a relatively safe approach to
improve the condition of individuals suffering from drug-resistant
epilepsy. Various side effects are related to the actual stimulation
and adjusting the stimulation settings can reduce these. However,
being a surgical procedure, VNS implantation involves certain
risks. Inserting a foreign body adds to these risks. Published
surgical and hardware complication frequencies are most often
reported as the relative frequency of patients that suffered from
complications. The number of additional surgeries patients
undergo may inﬂuence some of these frequencies. Stimulator
replacements are inevitable since stimulators run out of power. We
believe that a long follow-up time tends to increase certain
complication frequencies. In order to obtain more accurate
numbers, a different way of calculating these frequencies has
been used, as in Table 3. To be able to compare our data with
previous data, we also present ﬁgures as the proportion of patients
that suffered from complications.
In our study, 16.8% of the patients were affected by complica-
tions related to the surgery. With few exceptions, previous studies
present frequencies ranging from 2.5 to 12.5%.5,6,8–10,12–17 One
report noted that at least 23.5% of their patients suffered from
complications from the surgery.18 Cervical hypoesthesia was the
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relatively high surgical complication frequency is most likely
multifactorial. As described above, a long follow up time will most
certainly increase the numbers of complications. Our mean follow
time of 62 months is within the higher range of previous
studies.5,6,8–10,12–17 Scrutinizing the complications that appeared
in our material and comparing these with previous described one
can notice that apart from vocal cord palsy, of what we had a higher
frequency, our complication rates for speciﬁc complications were
within the same range as other studies. However, we report of
certain complications not previously described, e.g. puncture of the
jugular vein and keloid development. Noticeable was also the vast
number of different complications that was prevalent in our series.
We encountered 8 different types of complications related to
surgery. Previous studies report numbers ranging from 1 to 5 with
a mean rate of 1.9.5,6,8–10,12–17 Adjusting these ﬁgures to the
number of patients these studies comprehended there were 28.6
patients to every new type of complication compared to our 17.9.
We have no explanation for this ﬁnding. The criteria set for the
various complications may differ in the literature. Regarding the
cases of infections we included conditions that led to an active
treatment. This approach may overestimate the infection frequen-
cy. One patient received antibiotics in an outpatient clinic 930 days
after surgery for a suspected infection around the system. The
symptoms of the claimed infection allegedly then vanished. It can
be questioned whether or not this was an infection related to the
system.
In terms of hardware complications, reports of relative
incidences are between 0 and 20.8%.5,6,8,10,12,14–17,19 Our results
(16.8% npts) are consistent with these studies.
4.1. Surgical complications
4.1.1. Infection
We report 12 cases of infection in 10 (7.0% npts) of the patients.
Previous studies report infection rates from 0 to
10.9%.5,6,8,9,12,13,16–18,20–24 We treated superﬁcial infections suc-
cessfully with oral antibiotics, but in the deeper infections, device
explantation was unavoidable. Prophylactic antibiotics were
administered only during implantation. Prolonged antibiotic
treatment subsequent to surgery might be feasible to reduce the
incidence of infection. One study implementing this regime
reported an infection frequency of 0% in 36 patients treated.6
Whether or not the frequency of infection is higher after
additional surgery has not to our knowledge been assessed before.
Among our patients, we recognized a higher frequency of infection
after one reoperation and an even higher frequency after a second
than in patients with no reoperation. We made the same
observation with regard to stimulator replacements. This outcome
could imply that the absolute risk of infection at the site of the
stimulator is enhanced after every reoperation at this location. This
emphasises the need for stimulators with a longer battery life or
rechargeable stimulators.
With two exceptions, all our infections occurred at the location
of the stimulator. A concern of ours has been the risk of reinfection
after reimplantation if previous explantation due to infection
included only the stimulator and not the entire system. We noted a
higher risk of infection if only the stimulator was removed. Our
material is too small for conclusions to be drawn, but it
nevertheless suggests that the removal of the entire system is
necessary in order to reduce the risk of reinfection. Patel and
Edwards encouraged the same regime based on their own
experiences of reinfection and a review of present literature.25
In contrast to these reports, Wozniak et al. showed that early
removal of the stimulator and concealing the proximal end of the
lead in unaffected tissue followed by three to four weeks ofantibiotic treatment cured the infection and led to subsequent
successful reimplantation in three out of four patients.26 Although
the number of patients is small, these later results are promising as
they indicate that two additional interventions in the vicinity of
sensitive structures in the neck can be avoided in some cases of
infection. Further studies implementing this approach are needed
to determine its value.
4.1.2. Vocal cord palsy
Vocal cord palsy has previously been reported to affect 1–2.7%
of the patients and has usually been transient.5,6,12,21,22,24,27,28
Higher frequencies of this complication have been reported in
studies with small materials.3,19,29 Zalvan et al. presented two
cases of vocal cord palsy attributed to the surgery.30 Dissection in
order to reveal the vagus nerve, leading to disruption of the blood
supply in the area as well as clamping, heating and traction to the
nerve were mentioned as possible explanations of the symptom.
We experienced eight cases (5.6% npts) of vocal cord palsy. As
previous studies have suggested, the tendency for voice alteration
to normalize with time also applied to most of our patients.
Although studies have demonstrated the safety in removing
leads,31,32 complications following this intervention can occur.
Fibrosis in this region, subsequent to earlier lead insertion, makes
additional surgery here troublesome. We experienced one case of
vocal cord palsy after a lead replacement (3.8% of the lead
explantations and lead replacements), which persisted for at least
a year. Other studies have reported the same complication.27,33
Spuck et al. speculated that vocal cord palsy arising after surgery
could be age-dependent and predominantly affect adults.12We can
add support for this hypothesis as all our cases of vocal cord palsy
appeared in adults. Among the three cases of damage to the jugular
vein in our series, two appeared while attempting to remove leads.
With these experiences in mind, it might be favorable to leave the
old electrodes in place in cases where extensive scarring or ﬁbrosis
is prevalent. New electrodes can be inserted cephalad to the old.34
4.1.3. Cardiac complications
We report one intra-operative episode of bradycardia (0.7%
npts). The presence of cardiac branches emanating from the vagus
nerve has led to a concern that the treatment by vagus nerve
stimulation may affect the cardiac function. The VNS-system has
been tested under ECG surveillance intra-operatively and, al-
though they seldom occur, bradycardia and asystole are occasion-
ally reported during this session. The estimated incidence is 0.1%.35
Cardiac rhythm normalizes, either spontaneously or after decreas-
ing/discontinuation of stimulation and in some cases after the
administration of atropine.12,35,36 In spite of a previous event of
bradycardia/aystole during intra-operative testing, stimulation
has been observed to be well tolerated during subsequent
treatment.7,12,24 Increased sensitiveness to VNS under anesthesia
is one theory of this occurrence.36
Cardiac branches sprouting from the left vagus nerve predomi-
nantly modulate activity in the atrioventricular node whereas the
sinoatrial node receives branches mainly from the right.37 This is
the reason for stimulation of the left vagus nerve. Situations exist
where left vagus nerve stimulation is not possible, usually because
of previous infection in the area with subsequent tissue adhesion
around the vagus nerve. Although there are few data available,
right vagus nerve stimulation has been suggested as a viable option
in these cases.37–39 In our series, two devices were implanted
around the right vagus nerve and subsequent VNS treatment was
uneventful.
4.1.4. Other surgical complications
During the surgery, the surgeon must be aware of cutaneous
nerve branches that may transverse the surgical ﬁeld. Even though
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the patient and care should be taken to avoid this kind of
complication. As mentioned, we encountered one patient with
hypoesthesia post surgery (0.7% npts). This complication has
previously only rarely been described in the literature.18
In 2001, a case report was published of a patient developing
Horner syndrome after insertion of a vagus nerve stimulation
device.40 It was suggested that this condition was the result of a
transient dysfunction of third-order oculosympathetic ﬁbers
within the carotid sheath. The condition has since been described
only once more.18 We here report a third case of Horner syndrome
after vagus nerve stimulator insertion.
4.2. Technical complications
Among the technical complications, lead fracture is the most
common. This is a serious complication as it inevitable leads to
surgery to replace the lead. The surgery is technically challenging,
as it is necessary to proceed in scar tissue toward the nerve, with
the risk of damaging the nerve and other structures in this region.
We report 17 cases (11.9% npts) of lead fracture. Other authors
have presented ﬁgures ranging from 0.5 to 20.8%.6,9,12,14,15,20–22,29
Analysing all lead fractures and patients included in these studies
we calculated that 3.9% of the patients treated suffered from this
incident. Spuck et al. suggested that this complication is age-
dependent, as all their lead fractures occurred in children.12 This
was not the case in our results. All but ﬁve leads implanted were of
lead models 300 or 302. In our analysis of these two leads, no
statistical signiﬁcant difference in survival time was found.
Looking at the survival curve, the 300 lead seems to be more
susceptible for breakage though. The difference in observation
time between the two leads could be a contributing factor to the
reason that no statistical signiﬁcant difference was found. This
analysis can be redone in a couple of years to ﬁnd out if a difference
exists. Hopefully, the recently introduced new lead models will
reduce this serious complication.
Stimulators are usually solid and have only rarely been reported
as being the cause of non-functional devices.5,10,16 In our series, we
had to replace two stimulators which did not work properly (1.4%
npts). No trauma was mentioned prior to the malfunction.
However, a recently published article described one case of
post-traumatic stimulator dysfunction.12
4.3. Generally remarks and comparison
It is always difﬁcult to discuss complications to surgical
procedures. We have chosen to report every complication
irrespectively of its magnitude, as there is no general agreement
of what kind of an event constitutes a complication to a surgical
procedure or treatment. In the National Swedish Epilepsy Surgery
Register (NSESR), which compiles data from all Swedish epilepsy
surgery, complication is deﬁned as ‘‘an unwanted, unexpected, and
uncommon event after a diagnostic or therapeutic procedure’’.41
The complications are here graded as minor or major. A minor
complication is an event that resolves within 3 months and a major
complication is an event that affects activity of daily living and
lasts longer than 3 months. In the major complication group is also
included any signiﬁcant neurological deﬁcit even if it does not
affect activities of daily living. In correspondence to this deﬁnition
the infections could be regarded as minor complications but the
vocal cord palsies lasting longer than 3 moths (n = 4, 1.6% of
procedures) should be regarded as major complications. The
infection rate for therapeutic procedures reported in the study
from the NSESR was 5.3% and the total number of surgical
complications was 7.8% in relation to number of procedures, which
would be in the range of our 11.2% surgical complication rate inrelation to number of procedures. The number of major
complications would also be comparable between the paper by
Rydenhag and Silander,41 and our material (3.1% cf. 1.6%)
A comparable surgical procedure in neurosurgery would be the
implantation of deep brain stimulation (DBS). The DBS system
consists of an electrode, which is stereotactically introduced to a
certain point in the brain through a burr hole, then connected with
a cable, which is tunneled subcutaneously to a stimulator placed in
a subcutaneous pocket usually on the chest. In the literature we
have found a few recent papers speciﬁcally dealing with
complications to DBS surgery.42–47
The percentage of infection reported in these studies is in the
range of 2.5–8.5%. It is not explicitly formulated that the reported
infection frequencies are based on the number of primary
implantation, though reading the papers this seems to be the
case. This would mean that the reported infection frequencies are
in the same range of what we report in our primary implants.
The frequency of lead breakage in DBS surgery is reported to be
in the range of 0.9–6.7%42,44 which can be compared with the range
of what is reported for VNS 0.5–20.8%.6,9,12,14,15,20–22,29 This could
signal a deﬁnite need for improvement of the leads, which may
have been met by the introduction of new leads on the market. It
might also illustrate a need for changed surgical practice, as
Blomstedt and Hariz showed in their paper that with a change of
surgical practice the number of lead breakages seemed to be
reduced.42
It is not easy to evaluate complications to vagal nerve
stimulation in patients with refractory epilepsy. Many of the
patients are mentally disabled and are not able to describe certain
symptoms. The frequency of vocal cord palsy with subsequent
hoarseness could be underreported in the literature, as many
patients receiving treatment are not using their voice in a manner
that would permit the detection of vocal cord palsy. We are also
aware of the inherited weaknesses of a retrospective designed
study when analyzing long-term complications. Determining the
time at which a hardware complication occurs is prone to
inaccuracy and the same applies to the duration of vocal cord
palsies. One may suppose that complications might have been
missed as people seek medical care at other hospitals and
consequently, frequencies must be considered minimum esti-
mates. We would like to argue against this last assumption as the
patients have been assessed at our hospital at least once a year and
also because medical charts from local hospitals were collected for
the study.
5. Conclusions
In this series we report on surgical and technical complications
from our 16 years of experience with VNS treatment. Infection
following insertion of the VNS device and vocal cord palsy due to
damage to the vagus nerve are the most serious complications
related to the surgery. Avoiding unnecessary reoperations in order
to reduce the appearances of these complications are of great
importance. There seems to be an increased infection frequency
with increasing number of stimulator replacements. This empha-
sizes the importance of longer battery times or the need for
rechargeable devices. We noted that 10.5% of our leads between
the electrodes and the stimulator suffered from fracture. This rate
is too high to be considered acceptable. The leads have been
modiﬁed several times since the introduction of the treatment in
attempts to minimize this occurrence. In our material we noticed a
tendency for an old model of lead to be more susceptible to fracture
than a later model. Further studies are needed to evaluate the
possible superiority of the modiﬁed leads. Considering that VNS
therapy is a lifelong therapy, the importance of long-term follow-
up must be stressed.
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